The Peugeot 106 is a supermini produced by French automaker Peugeot between 1991 and 2003. Launched in September 1991, it was Peugeot's entry level offering throughout its production life, and was initially sold only as a three-door hatchback, with a five-door hatchback joining the range in the beginning of 1992. Production ended in July 2003.

2023年11月2日 · MB-106, a fully human 3 rd-generation CD20-targeted CAR-T product with both 4-1BB and CD28 costimulatory domains, had high overall response rate (100%) and complete response (CR) rate (91%) in follicular lymphoma (FL) patients at doses ≥ 3.3×10 6 cells/kg in a single institution trial (Shadman et al., 17-ICML, 2023). We seek to replicate the ...

MB-106是一种全人、第三代、CD20靶向CAR-T细胞疗法 ，含有4-1BB和CD28共刺激结构域、改良的IgG1间隔区消除了FcR结合，目前正由Mustang Bio与美国弗雷德·哈钦森癌症研究中心（Fred Hutch）合作开发。

2020年11月5日 · We present interim results of our ongoing phase I/II clinical trial investigating safety and efficacy CD20 CAR-T for high-risk B-NHLs (NCT03277729). Methods: MB-106 is a fully human third-generation CD20-targeted CAR-T with both 4-1BB and CD28 costimulatory domains. We use a continuous reassessment method dose escalation design to find the ...

MB-106是一款靶向CD20的 自体CAR-T细胞，被优化为全人源抗体的第3代CAR。 MB-106由Fred Hutchinson癌症研究中心（Fred Hutch）开发，于2017年独家授权给野马生物。 在第62届 美国血液学会 （ASH）年会上，野马生物公布了由Fred Hutch赞助的MB-106针对复发或难治性B细胞非霍奇金淋巴瘤（NHL）的1/2期临床试验（NCT03277729）的研究数据。 数据显示，9例可评估的患者中， 总缓解率（ORR）为89%， 完全缓解率 （CR）为44%；在滤泡性淋巴瘤患 …

2023年12月8日 · Indolent B-cell non-Hodgkin lymphomas (NHL) remain incurable despite multiple therapeutic options, including chemoimmunotherapy, targeted therapies, bispecific antibodies, and CD19-targeted chimeric antigen receptor (CAR) T-cells. MB-106 is a fully human 3rd-generation CD20-targeted CAR T-cell product with 4-1BB and CD28 costimulatory domains.

MB-106 is a third generation fully human CD20 targeted CAR-T cell therapy for treatment of B-NHLs. Enrollment continues for the current study. All CD20+ NHL are eligible. CLL pts are also eligible with the new amendment (NCT03277729)

2021年11月5日 · MB-106 is a fully human 3rd-generation CD20-targeted CAR-T product with both 4-1BB and CD28 costimulatory domains. We present results of our ongoing phase I/II clinical trial investigating safety and efficacy of CD20 CAR-T for high-risk B-NHLs and CLL (NCT03277729).

2024年6月19日 · 日前，Mustang Bio公司公布其在研CAR-T细胞疗法MB-106进行中的1/2期临床试验最新数据。 分析显示，接受该疗法的华氏巨球蛋白血症（WM）患者的总缓解率（ORR）高达90%，其中一位患者持久完全缓解达31个月，这些患者在治疗前均接受过大量前期治疗。 根据新闻稿，目前仍未有CAR-T疗法获FDA批准用于治疗WM患者。 试验中的所有十例患者均曾接受过布鲁顿酪氨酸激酶抑制剂（BTKi）的治疗，并且在接受BTKi治疗期间病情持续恶化。 患者之前接 …

2021年11月4日 · MB-106 has been optimized as a third-generation CAR derived from a fully human antibody and is currently in a Phase 1/2 open-label, dose-escalation trial at Fred Hutch in patients with B-NHL and CLL. Additional information on the trial can be found at http://www.clinicaltrials.gov using the identifier NCT03277729 .